Inhibition of PTEN expression and activity by angiotensin II induces proliferation and migration of vascular smooth muscle cells

Journal of Cellular Biochemistry

Volumn 114, Issue 1, 2013, Pages 174-182

  Dong, Xue ^a   Yu, Lu Gang ^b   Sun, Rong ^c   Cheng, Yan Na ^a   Cao, Hua ^a   Yang, Kang Min ^a   Dong, Yi Ning ^a   Wu, Yan ^a   Guo, Xiu Li ^a  

^a SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c Shandong Academy of Traditional Chinese Medicine   (China)

Author keywords

ANGIOTENSIN II; MIGRATION; PROLIFERATION; PTEN; VASCULAR SMOOTH MUSCLE CELLS

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; ADENOVIRUS VECTOR; ANGIOTENSIN II; FOCAL ADHESION KINASE; LOSARTAN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; ROSIGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME PHOSPHORYLATION; GENE OVEREXPRESSION; GENETIC TRANSDUCTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE;

ADENOVIRIDAE; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; AORTA, THORACIC; CELL MOVEMENT; CELL PROLIFERATION; FOCAL ADHESION KINASE 1; GENE EXPRESSION REGULATION; LOSARTAN; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NITRILES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RATS; SIGNAL TRANSDUCTION; SULFONES; THIAZOLIDINEDIONES; TISSUE CULTURE TECHNIQUES; TRANSDUCTION, GENETIC; VASODILATOR AGENTS;

ADENOVIRIDAE;

EID: 84869473350     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.24315     Document Type: Article

References (24)

1. Cantley LC, Neel BG,. 1999. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 96: 4240-4245.
2. Chatzizacharias NA, Kouraklis GP, Theocharis SE,. 2007. Focal adhesion kinase: A promising target for anticancer therapy. Expert Opin Ther Targets 11: 1315-1328.
3. Chung JH, Ostrowski MC, Romigh T, Minaguchi T, Waite KA, Eng C,. 2006. The ERK1/2 pathway modulates nuclear PTEN-mediated cell cycle arrest by cyclin D1 transcriptional regulation. Hum Mol Genet 15: 2553-2559.
4. 2 regulates the angiogenic phenotype via PTEN oxidation. J Biol Chem 280: 16916-16924.
5. Garl PJ, Wenzlau JM, Walker HA, Whitelock JM, Costell M, Weiser-Evans MC,. 2004. Perlecan-induced suppression of smooth muscle cell proliferation is mediated through increased activity of the tumor suppressor PTEN. Circ Res 94: 175-183.
6. Hao LS, Zhang XL, An JY, Karlin J, Tian XP, Dun ZN, Xie SR, Chen S,. 2009. PTEN expression is down-regulated in liver tissues of rats with hepatic fibrosis induced by biliary stenosis. APMIS 117: 681-691.
7. 2 in NF-κB activation. Free Radic Biol Med 45: 885-896.
8. Kotelevets L, van Hengel J, Bruyneel E, Mareel M, van Roy F, Chastre E,. 2001. The lipid phosphatase activity of PTEN is critical for stabilizing inter cellular junctions and reverting invasiveness. J Cell Biol 155: 1129-1135.
9. Kyotani Y, Zhao J, Tomita S, Nakayama H, Isosaki M, Uno M, Yoshizumi M,. 2010. Olmesartan inhibits angiotensin II-Induced migration of vascular smooth muscle cells through Src and mitogen-activated protein kinase pathways. J Pharmacol Sci 113: 161-168.
10. Lee SR, Yang KS, Kwon J, Lee C, Jeong W, Rhee SG,. 2002. Reversible inactivation of the tumor suppressor PTEN by H2O2. J Biol Chem 277: 20336-20342.
11. Maehama T, Dixon JE,. 1999. PTEN: A tumor suppressor that functions as a phospholipid phosphatase. Trends Cell Biol 9: 125-128.
12. Mitra AK, Jia G, Gangahar DM, Agrawal DK,. 2009. Temporal PTEN inactivation causes proliferation of saphenous vein smooth muscle cells of human CABG conduits. J Cell Mol Med 13: 177-187.
13. Mourani PM, Garl PJ, Wenzlau JM, Carpenter TC, Stenmark KR, Weiser-Evans MC,. 2004. Unique, highly proliferative growth phenotype expressed by embryonic and neointimal smooth muscle cells is driven by constitutive Akt, mTOR, and p70S6K signaling and is actively repressed by PTEN. Circulation 109: 1299-1306.
14. Oudit GY, Penninger JM,. 2009. Cardiac regulation by phosphoinositide 3-kinases and PTEN. Cardiovasc Res 82: 250-260.
15. Patel L, Pass I, Coxon P, Downes CP, Smith SA, Macphee CH,. 2001. Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN. Curr Biol 11: 764-768.
16. Qian ZJ, Jung WK, Byun HG, Kim SK,. 2008. Protective effect of an antioxidative peptide purified from gastrointestinal digests of oyster, Crassostrea gigas against free radical induced DNA damage. Bioresour Technol 99: 3365-3371.
17. Schwartzbauer G, Robbins J,. 2001. The tumor suppressor gene PTEN can regulate cardiac hypertrophy and survival. J Biol Chem 276: 35786-35793.
18. Steelman LS, Bertrand FE, McCubrey JA,. 2004. The complexity of PTEN: Mutation, marker and potential target for therapeutic intervention. Expert Opin Ther Targets 8: 537-550.
19. Tamguney T, Stokoe D,. 2007. New insights into PTEN. J Cell Sci 120: 4071-4079.
20. Tristano AG, Castejon AM, Castro A, Cubeddu LX,. 2007. Effects of statin treatment and withdrawal on angiotensin II-induced phosphorylation of p38 MAPK and ERK1/2 in cultured vascular smooth muscle cells. Biochem Biophys Res Commun 353: 11-17.
21. Wang S, Cheng Z, Yang X, Deng K, Cao Y, Chen H, Pan L,. 2010. Effect of wild type PTEN gene on proliferation and invasion of multiple myeloma. Int J Hematol 92: 83-94.
22. Wildroudt ML, Freeman EJ,. 2006. Regulation of Akt by arachidonic acid and phosphoinositide 3-kinase in angiotensin II-stimulated vascular smooth muscle cells. Biochim Biophys Acta 1761: 11-16.
23. Xia D, Srinivas H, Ahn YH, Sethi G, Sheng X, Yung WK, Xia Q, Chiao PJ, Kim H, Brown PH, Wistuba II, Aggarwal BB, Kurie JM,. 2007. Mitogen-activated protein kinase-4 promotes cell survival by decreasing PTEN expression through an NF kappa B-dependent pathway. J Biol Chem 282: 3507-3519.
24. Zhang W, Wu N, Li Z, Wang L, Jin J, Zha XL,. 2006. PPARgamma activator rosiglitazone inhibits cell migration via upregulation of PTEN in human hepatocarcinoma cell line BEL-7404. Cancer Biol Ther 5: 1008-1014.